Physician profile
Daniel J Milam
NPI 1568784205
$3,406.80
in general payments reported to CMS, 2019-2025
21 companies · $739 in 2025
The $739 reported for 2025 was more than what 83% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $259 · 2022: $580 · 2023: $786 · 2024: $1,044 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,568.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $691.74 | 2021-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Grifols USA, LLC | $413.89 | 2021-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $359.44 | 2022-2024 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $291.39 | 2021-2025 | Fasenra, Airsupra, Tagrisso |
| Regeneron Healthcare Solutions, INC. | $238.24 | 2021-2025 | Dupixent |
| Genzyme Corporation | $235.66 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $220.36 | 2023-2025 | Keytruda, Winrevair, Recarbrio |
| Mylan Specialty L.P. | $198.43 | 2021-2024 | Yupelri |
| United Therapeutics Corporation | $126.87 | 2021-2025 | Tyvaso, Tyvaso |
| Glaxosmithkline, LLC. | $126.61 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Inspire Medical Systems, INC. | $101.07 | 2023-2024 | Inspire |
| Electromed, INC. | $73.09 | 2023-2024 | Smartvest |
| Verona Pharma, INC. | $59.08 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $53.24 | 2023 | Glassia, Hyqvia |
| Janssen Pharmaceuticals, INC | $45.41 | 2023-2024 | Xarelto |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $40.76 | 2022 | |
| Viatris Specialty LLC | $38.22 | 2025 | Yupelri |
| Amgen INC. | $37.90 | 2024-2025 | Tavneos |
| Baxter Healthcare | $23.47 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.58 | 2025 | |
| Axsome Therapeutics, INC. | $13.35 | 2024 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Milam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.